Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Fasnall HCl
Cat. No.:
OB0225LY-0029
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by HPLC.
Size:
Product Overview
Description:
Fasnall HCl is a novel fatty acid synthase inhibitor designed to stop the growth of cancer cells by inhibiting fatty acid synthesis.
CAS No.:
929978-58-5
Formula:
C19H23ClN4S
Formula Weight:
374.93
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Fasnall HCl can be used in drug discovery and development, especially in therapeutic research for obesity-related cancers.
Library Information
Targets:
Fatty acid synthase
Receptors:
Fatty acid synthase
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
c10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
22.5 mg/mL; 60.01 mM
